Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion (Nature Communications, (2015), 6, 1, (10044), 10.1038/ncomms10044);Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

Nature Communications

Volumn 6, Issue , 2015, Pages

  Nguyen, Van T M ^a   Barozzi, Iros ^b   Faronato, Monica ^a   Lombardo, Ylenia ^a   Steel, Jennifer H ^a   Patel, Naina ^a   Darbre, Philippa ^c   Castellano, Leandro ^a   Gyorffy, Balázs ^d   Woodley, Laura ^e   Meira, Alba ^a   Patten, Darren K ^a   Vircillo, Valentina ^f   Periyasamy, Manikandan ^a   Ali, Simak ^a   Frige, Gianmaria ^b   Minucci, Saverio ^b   Coombes, R Charles ^a   Magnani, Luca ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF READING   (United Kingdom)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e CHARING CROSS HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; MEVINOLIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAMOXIFEN; TERBINAFINE; TRANSCRIPTOME; 27-HYDROXYCHOLESTEROL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CHOLESTEROL; CHOLESTEROL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CELLS AND CELL COMPONENTS; DRUG RESISTANCE; ENDOCRINOLOGY; PHENOTYPE; STEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER HORMONE THERAPY; CELL INVASION; CHOLESTEROL SYNTHESIS; CHROMATIN STRUCTURE; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; RNA TRANSCRIPTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETIC EPIGENESIS; GENETICS; IMMUNOHISTOCHEMISTRY; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR INVASION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BIOSYNTHETIC PATHWAYS; BLOTTING, WESTERN; BREAST NEOPLASMS; CHOLESTEROL; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; MCF-7 CELLS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; REAL-TIME POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84948679022     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-11569-z     Document Type: Erratum

References (55)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
2. Palmieri, C., Patten, D. K., Januszewski, A., Zucchini, G. & Howell, S. J. Breast cancer: current and future endocrine therapies. Mol. Cell. Endocrinol. 382, 695-723 (2014).
3. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 1-13, doi:10. 1038/nrc2713 (2009).
4. Xie, W. et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 153, 1134-1148 (2013).
5. Consortium, T. E. P. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 488, 57-74 (2012).
6. Polo, J. M. et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151, 1617-1632 (2012).
7. Magnani, L. et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl Acad. Sci. USA 110, E1490-E1499 (2013).
8. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
9. Suva, M. L. et al. Reconstructing and reprogramming the tumor-propagating potentialof glioblastoma stem-like cells. Cell 157, 1-15 (2014).
10. Ernst, J. & Kellis, M. Nat Biotechnol 2010 Ernst. Nat. Biotechnol. 28, 817-838 (2010).
11. Whyte, W. A. et al. Master transcription factors and mediator establish superenhancers at key cell identity genes. Cell 153, 307-319 (2013).
12. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
13. Malik, A. N. et al. Genome-wide identification and characterization of functional neuronal activity-dependent enhancers. Nat. Neurosci. 17, 1330-1339 (2014).
14. Stasevich, T. J. et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 516, 272-275 (2014).
15. Shaw, L. E., Sadler, A. J., Pugazhendhi, D. & Darbre, P. D. Changes in oestrogen receptor-a and-b during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 99, 19-32 (2006).
16. Martin, L. A. et al. An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 76, 772-776 (2011).
17. Magnani, L., Ballantyne, E. B., Zhang, X. & Lupien, M. PBX1 genomic pioneer function drives ERa signaling underlying progression in breast cancer. PLoS Genet. 7, e1002368 (2011).
18. Magnani, L. et al. The pioneer factor PBX1 is a novel driver of metastatic progression in ERa-positive breast cancer. Oncotarget 6, 21878-21891 (2015).
19. Magnani, L., Eeckhoute, J. & Lupien, M. Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 27, 465-474 (2011).
20. Magnani, L. & Lupien, M. Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. Mol. Cell. Endocrinol. 382, 633-641 (2014).
21. Jozwik, K. M. & Carroll, J. S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381-385 (2012).
22. Tyson, J. J. et al. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat. Rev. Cancer 11, 523-532 (2011).
23. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
24. Miller, W. R. & Larionov, A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 12, R52 (2010).
25. Bertucci, F. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66, 4636-4644 (2006).
26. Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat. Genet. 46, 136-143 (2014).
27. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
28. Dowen, J. M. et al. Control of cell identity genes occurs in insulated neighborhoodsin mammalian chromosomes. Cell 159, 374-387 (2014).
29. Neph, S. et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 488, 83-90 (2012).
30. Jeon, T.-I. & Osborne, T. F. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 23, 65-72 (2012).
31. Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187-197 (1993).
32. Briggs, M. R., Yokoyama, C., Wang, X., Brown, M. S. & Goldstein, J. L. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J. Biol. Chem. 268, 14490-14496 (1993).
33. Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882-892 (2009).
34. Nora, E. P. et al. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485, 381-385 (2012).
35. Sanchez, C. G. et al. Preclinical modeling of combinedphosphatidylinositol-3-kinase inhibition withendocrine therapy for estrogen receptor-positivebreast cancer. Breast Cancer Res. 13, R21 (2011).
36. Umetani, M. et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13, 1185-1192 (2007).
37. Phimister, E. G., Warner, M. & Gustafsson, J.-Å. On estrogen, cholesterol metabolism, and breast cancer. N. Engl. J. Med. 370, 572-573 (2014).
38. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43 (2005).
39. Wu, Q. et al. 27-Hydroxycholesterol promotescell-autonomous, ER-positive breast cancer growth. Cell Rep. 5, 637-645 (2013).
40. Lupien, M. et al. Growth factor stimulation induces a distinct ER cistrome underlying breast cancer endocrine resistance. Genes Dev. 24, 2219-2227 (2010).
41. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
42. Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258 (2012).
43. Miller, W. R. et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to Letrozole. J. Clin. Oncol. 27, 1382-1387 (2009).
44. Parris, T. Z. et al. Frequent MYC coamplification and DNA hypomethylation ofmultiple genes on 8q in 8p11-p12-amplified breast carcinomas. Oncogenesis 3, e95-e98 (2014).
45. Yamaguchi, N. et al. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem. Biophys. Res. Commun. 365, 711-717 (2008).
46. Lin, M.-L. et al. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget 6, 21685-21703 (2015).
47. Ahern, T. P., Lash, T. L., Damkier, P., Christiansen, P. M. & Cronin-Fenton, D. P. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 15, e461-e468 (2014).
48. Ahern, T. P. et al. Statin prescriptions and breast cancer recurrence risk: a Danish Nationwide Prospective Cohort Study. J. Natl Cancer Inst. 103, 1461-1468 (2011).
49. Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 371, 107-118 (2014).
50. Bao, T., Blackford, A. L. & Stearns, V. Effect of simvastatin on the pharmacokinetics of anastrozole. Breast Cancer Res. Treat. 131, 709-711 (2011).
51. Kobayashi, Y. et al. Mevalonate pathway antagonist inhibits proliferation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin. Cancer Res. doi: 10. 1158/1078-0432. CCR-14-3368 (2015).
52. Clendening, J. W. et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 115, 4787-4797 (2010).
53. Lombardo, Y. et al. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proc. Natl Acad. Sci. USA 109, 16558-16563 (2012).
54. Warita, K. et al. Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci. Rep. 4, 7593 (2014).
55. Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).